VX19-147-007
23 evidence topics · 3 sources
Objective
Location and study date
Study dates and status in the registry record
| Field | Registry entry |
|---|---|
| Recruitment status | “Completed” |
| Study start (actual) | “2023-06-12” |
| Primary completion (actual) | “2024-06-12” |
| Study completion (actual) | “2024-06-12” |
| First posted | “2023-05-18” |
| Last update posted | “2024-07-12” |
| Other study ID numbers | “VX19-147-007” |
Presentation at the NKF 2026 Spring Clinical Meetings
Study design
Design details in the registry record
| Field | Registry entry |
|---|---|
| Study type | “Interventional” |
| Phase | “Phase 1” |
| Primary purpose | “Basic Science” |
| Allocation | “Randomized” |
| Interventional model | “Sequential Assignment” |
| Masking | “None (Open Label)” |
Comparison with matched healthy participants
Eligibility criteria
Severe renal impairment not on dialysis
Age range and healthy volunteers
| Field | Registry entry |
|---|---|
| Ages eligible | “18 Years to 80 Years” |
| Sexes eligible | “All” |
| Accepts healthy volunteers | “Yes” |
Treatment
Study outcomes
Rationale for using plasma cmax and AUC0-inf as the primary endpoints
Registered primary and secondary outcomes
Renal clearance in the healthy-adult studies
“Renal clearance was a minor excretion pathway for inaxaplin; dose adjustments are therefore not anticipated for the intended patient population which will include patients with renal function impairment (online Table S2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Enrollment in the registry record
| Field | Registry entry |
|---|---|
| Enrollment (actual) | “16” |
Enrollment reported in the congress abstract
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
Exposure in severe renal impairment compared with healthy matches
Health-related quality of life and patient-reported outcomes
Not applicable.
Safety results
Safety in the renal and hepatic impairment studies
Study limitations
Summary: study limitations
VX19-147-007 gave a single 45 mg dose to 16 participants: 8 with severe renal impairment (estimated glomerular filtration rate below 30 mL/min and not on dialysis) and 8 matched healthy participants. The results are available only as a congress abstract, which reports the geometric least squares mean ratio as “<120%” without point estimates or confidence intervals and reports safety only as “generally safe and well tolerated”. The ClinicalTrials.gov record lists no posted results. Participants on dialysis and multiple-dose exposure were not studied, and five of the six abstract authors list a Vertex Pharmaceuticals affiliation.